← Leaderboards
Daniela Salvemini
University Of Maryland Baltimore
$13,229,020
Attributed
$22,223,967
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,223,967 · 18
By mechanism
R01$17,930,346 · 10
R61$1,511,970 · 1
R21$1,149,872 · 3
RC1$974,024 · 1
R43$657,755 · 3
Top collaborators
- Susan A Farr8 shared
- Simon Akerman6 shared
- Christopher K Arnatt4 shared
- Cobi J Heijnen4 shared
- Todd W Vanderah3 shared
- William Neumann2 shared
- Marcela Romero-Reyes2 shared
- Gina L.C. Yosten2 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Simon Akerman$1,348,526
- Jane V Aldrich$13,431,473
- Joyce Teixeira Da Silva$2,580,045
- Jin Y Ro$11,441,623
- Marcela Romero-Reyes$628,530
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseLinkInflammatoryAttenuatedSignal TransductionMolecularNeuroinflammationMedicalPainNeurogliaCytokineTherapeutic InterventionNeuronsReceptorResponsePreventGenetic ApproachSpinalAffectKnockout MiceTargeted TreatmentChronicPharmacologyBase
Grant awards (49)
Molecular basis for functional S1PR1 antagonists in the treatment of comorbid migraine and temporomandibular disorders$570,062
R01 · FY2025 · NS
Uncovering the roles of oxysterols in neuropathic pain$545,271
R01 · FY2025 · NS · contact PI
Fingolimod and Ozanimod for the treatment and prevention of chemobrain$502,411
R01 · FY2025 · CA · contact PI
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine$472,920
R01 · FY2025 · NS
Development of selective GPR34 antagonists for the treatment of neuropathic pain$1,511,970
R61 · FY2024 · NS · contact PI
Molecular basis for functional S1PR1 antagonists in the treatment of comorbid migraine and temporomandibular disorders$620,278
R01 · FY2024 · NS
Fingolimod and Ozanimod for the treatment and prevention of chemobrain$458,752
R01 · FY2024 · CA · contact PI
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine$458,732
R01 · FY2024 · NS
GPR160 antibody development for cancer treatment$168,212
R21 · FY2024 · CA · contact PI
Uncovering the roles of oxysterols in neuropathic pain$582,767
R01 · FY2023 · NS · contact PI
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine$472,920
R01 · FY2023 · NS
Fingolimod and Ozanimod for the treatment and prevention of chemobrain$461,866
R01 · FY2023 · CA · contact PI
Novel therapeutic approaches for traumatic brain injury induced cognitive deficits$331,406
R01 · FY2023 · NS · contact PI
GPR160 antibody development for cancer treatment$212,479
R21 · FY2023 · CA · contact PI
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicity$529,790
R01 · FY2022 · CA · contact PI
Uncovering the roles of oxysterols in neuropathic pain$520,274
R01 · FY2022 · NS · contact PI
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine$498,920
R01 · FY2022 · NS
Fingolimod and Ozanimod for the treatment and prevention of chemobrain$442,415
R01 · FY2022 · CA · contact PI
Novel therapeutic approaches for traumatic brain injury induced cognitive deficits$331,406
R01 · FY2022 · NS · contact PI
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicity$565,356
R01 · FY2021 · CA · contact PI
Novel therapeutic approaches for traumatic brain injury induced cognitive deficits$318,661
R01 · FY2021 · NS · contact PI
Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponses$565,658
R01 · FY2020 · DA · contact PI
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicity$565,356
R01 · FY2020 · CA · contact PI
Novel therapeutic approaches for traumatic brain injury induced cognitive deficits$324,915
R01 · FY2020 · NS · contact PI
Isolation of GPR160 for biochemical analysis of the activation mechanism and development of a high throughput screening assay to identify small molecule inhibitors$151,455
R01 · FY2020 · NS · contact PI
Discovery and validation of a novel orphan GPCR as a target for therapeutic intervention in neuropathic pain$2,156,764
R01 · FY2019 · NS · contact PI
Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponses$565,658
R01 · FY2019 · DA · contact PI
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicity$548,396
R01 · FY2019 · CA · contact PI
Role of opioid-induced S1P/S1PR1 axis activation in neuroinflammatory reponses$591,350
R01 · FY2018 · DA · contact PI
A3AR agonists as a novel approach to mitigate chemotherapy induced neurotoxicity$578,231
R01 · FY2018 · CA · contact PI
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy$311,250
R01 · FY2017 · CA · contact PI
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy$299,746
R01 · FY2016 · CA · contact PI
Preserving opioid analgesia using a novel adenosinergic approach$187,481
R21 · FY2016 · DA · contact PI
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy$299,746
R01 · FY2015 · CA · contact PI
Preserving opioid analgesia using a novel adenosinergic approach$189,375
R21 · FY2015 · DA · contact PI
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy$290,754
R01 · FY2014 · CA · contact PI
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy$312,246
R01 · FY2013 · CA · contact PI
Role of peroxynitrite in morphine hyperalgesia and tolerance$327,484
R01 · FY2012 · DA · contact PI
Role of peroxynitrite in morphine hyperalgesia and tolerance$327,402
R01 · FY2011 · DA · contact PI
Targeting the relief of chronic pain with orally active peroxynitrite decompositi$474,025
RC1 · FY2010 · AR
Role of peroxynitrite in morphine hyperalgesia and tolerance$337,448
R01 · FY2010 · DA · contact PI
Targeting the relief of chronic pain with orally active peroxynitrite decompositi$499,999
RC1 · FY2009 · AR
Role of peroxynitrite in morphine hyperalgesia and tolerance$340,774
R01 · FY2009 · DA · contact PI
Role of ceramide in morphine hyperalgesia and tolerance$180,575
R21 · FY2009 · DA · contact PI
Role of peroxynitrite in morphine hyperalgesia and tolerance$351,506
R01 · FY2008 · DA · contact PI
Role of ceramide in morphine hyperalgesia and tolerance$211,750
R21 · FY2008 · DA · contact PI
SODm for Management of Ischemic Heart Disease$261,230
R43 · FY2001 · HL
M40403 and IL-2 Induced Hypotension$104,000
R43 · FY2001 · CA
SUPEROXIDE DISMUTASE MIMETICS FOR MANAGEMENT OF PAIN$292,525
R43 · FY2000 · DA